We are live on
!
Find out more
PR
PSP Research Portfolio holdings
AUM
$188M
This Fund
S&P 500
This Quarter
Est. Return
+15.6%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$188M
AUM Growth
+$46.6M
(+33%)
Cap. Flow
+$25.8M
Cap. Flow
% of AUM
13.71%
Top 10 Holdings %
Top 10 Hldgs %
88.03%
Holding
89
New
10
Increased
1
Reduced
31
Closed
14
Avg Time Held
1.5
quarters
Top 10 Avg Time Held
0.4
quarters
Top 20 Avg Time Held
0.6
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P Biotech ETF
XBI
|
+$38.5M |
| 2 |
Liquidia Corp
LQDA
|
+$268K |
| 3 |
Jazz Pharmaceuticals
JAZZ
|
+$213K |
| 4 |
ArriVent BioPharma
AVBP
|
+$208K |
| 5 |
Krystal Biotech
KRYS
|
+$207K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Sera Prognostics
SERA
|
+$4.87M |
| 2 |
DFTX
Definium Therapeutics
DFTX
|
+$613K |
| 3 |
Tyra Biosciences
TYRA
|
+$613K |
| 4 |
Cytokinetics
CYTK
|
+$547K |
| 5 |
CMPS
Compass Pathways
CMPS
|
+$538K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 85.52% |
| 2 | Healthcare | 14.48% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
ORKA
51
Oruka Therapeutics
ORKA
$5.44B
| $286K | 0.15% |
3,000
-1,968
| -40% | -$131K |
2026 Q1
1 quarter
|
|
52
Supernus Pharmaceuticals
SUPN
$2.48B
| $279K | 0.15% |
6,000
| – | – |
2025 Q4
2 quarters
|
|
53
CRISPR Therapeutics
CRSP
$5.16B
| $273K | 0.15% |
5,000
-4,500
| -47% | -$237K |
2025 Q4
2 quarters
|
|
54
Zymeworks
ZYME
$1.85B
| $261K | 0.14% |
10,000
| – | – |
2025 Q4
2 quarters
|
|
|
55
Krystal Biotech
KRYS
$9.82B
| $257K | 0.14% |
+692
| New | +$207K |
2026 Q2
0 quarters
|
|
|
CMPS
56
Compass Pathways
CMPS
$1.66B
| $255K | 0.14% |
18,000
-53,000
| -75% | -$538K |
2026 Q1
1 quarter
|
|
57
Xenon Pharmaceuticals
XENE
$3.53B
| $254K | 0.13% |
4,200
| – | – |
2025 Q4
2 quarters
|
|
58
Axsome Therapeutics
AXSM
$8.82B
| $245K | 0.13% |
1,000
-1,845
| -65% | -$400K |
2026 Q1
1 quarter
|
|
|
59
ArriVent BioPharma
AVBP
$825M
| $245K | 0.13% |
+7,041
| New | +$208K |
2026 Q2
0 quarters
|
|
60
Dianthus Therapeutics
DNTH
$4.61B
| $244K | 0.13% |
2,500
-2,500
| -50% | -$218K |
2025 Q4
2 quarters
|
|
|
61
Jazz Pharmaceuticals
JAZZ
$14.2B
| $234K | 0.12% |
+971
| New | +$213K |
2026 Q2
0 quarters
|
|
62
Kodiak Sciences
KOD
$6.28B
| $234K | 0.12% |
6,000
-4,000
| -40% | -$156K |
2025 Q4
2 quarters
|
|
63
Revolution Medicines
RVMD
$40.7B
| $225K | 0.12% |
+1,200
| New | +$175K |
2026 Q2
0 quarters
|
|
64
BridgeBio Pharma
BBIO
$12.8B
| $223K | 0.12% |
3,000
-3,000
| -50% | -$210K |
2025 Q4
2 quarters
|
|
65
Rhythm Pharmaceuticals
RYTM
$6.25B
| $222K | 0.12% |
+2,000
| New | +$181K |
2026 Q2
0 quarters
|
|
66
Denali Therapeutics
DNLI
$3.11B
| $218K | 0.12% |
+8,463
| New | +$174K |
2026 Q2
0 quarters
|
|
67
Arrowhead Research
ARWR
$8.86B
| $212K | 0.11% |
+2,600
| New | +$192K |
2026 Q2
0 quarters
|
|
68
Scholar Rock
SRRK
$5.14B
| $210K | 0.11% |
+3,827
| New | +$185K |
2026 Q2
0 quarters
|
|
69
Edgewise Therapeutics
EWTX
$4.24B
| $203K | 0.11% |
5,000
-1,500
| -23% | -$51.7K |
2026 Q1
1 quarter
|
|
70
Amylyx Pharmaceuticals
AMLX
$3.53B
| $195K | 0.1% |
10,838
| – | – |
2025 Q4
2 quarters
|
|
71
CytomX Therapeutics
CTMX
$560M
| $148K | 0.08% |
+39,400
| New | +$150K |
2026 Q2
0 quarters
|
|
72
Ocular Therapeutix
OCUL
$1.66B
| $147K | 0.08% |
15,000
| – | – |
2025 Q4
2 quarters
|
|
73
EyePoint Inc
EYPT
$293M
| $143K | 0.08% |
10,000
| – | – |
2025 Q4
2 quarters
|
|
74
Oric Pharmaceuticals
ORIC
$1.24B
| $141K | 0.07% |
13,000
| – | – |
2026 Q1
1 quarter
|
|
75
Olema Pharmaceuticals
OLMA
$684M
| $125K | 0.07% |
10,000
| – | – |
2025 Q4
2 quarters
|
|
Similar funds
IJWM
TCPG
KCPT
DWS
RMSCM
AWP
NCPF
CFP
PSP Research's Q2 2026 Portfolio in Review
As of Q2 2026, PSP Research held 89 positions worth $188M, up 33% from $141M the previous quarter. Its ten largest holdings account for 88% of the portfolio.
PSP Research deployed $25.8M of net new capital in Q2 2026, opening 10 new positions and adding to 1 existing holding. Its largest new stake was Liquidia Corp: 5,000 shares worth $399K.
By sector, the portfolio is most concentrated in Miscellaneous at 86% of assets, up from 76% a quarter earlier, followed by Healthcare.
On the sell side, the largest reduction was Definium Therapeutics, an estimated $613K trimmed.
- PSP Research's largest Q2 2026 buy was Liquidia Corp: 5,000 shares worth $399K.
- PSP Research added most to State Street SPDR S&P Biotech ETF in Q2 2026, an estimated $38.5M increase.
- PSP Research's biggest Q2 2026 reduction was Definium Therapeutics, cutting an estimated $613K.
- PSP Research fully exited Sera Prognostics in Q2 2026, selling an estimated $4.87M.
- PSP Research's ten largest holdings make up 88% of its $188M portfolio in Q2 2026.
- PSP Research opened 10 new positions and closed 14 in Q2 2026.
- PSP Research's portfolio value rose 33% quarter-over-quarter to $188M.
Based on PSP Research's 13F filing for Q2 2026, filed 9 Jul 2026.